DFS, OS Benefit Maintained With Adjuvant Atezolizumab vs BSC in Stage II/IIIA NSCLC

Long-term DFS and OS outcomes with adjuvant atezolizumab in stage II to IIIA NSCLC were consistent with prior data from the IMpower010 trial.

Related Keywords

,Winston Chen ,Heathera Wakelee ,Stanford Cancer Institute ,Phyllis Huang Professor ,Stanford Medicine ,Medical Oncology ,